Skip to Main Content

Sawai News

Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs

Osaka, Japan –August 15, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six compounds with 13 strengths of generic drugs. Among the six compounds, four compounds, Mirtazapine, Atomoxetine Hydrochloride, Tramadol Hydrochloride / Acetaminophen and Capecitabine, are approved for the first ...
Read More

MHLW Approves New Indication for OSELTAMIVIR Capsules 75mg [SAWAI] / Dry Syrup 3% [SAWAI]

Osaka, Japan –June 6, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OSELTAMIVIR  Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI]*. This approval expands the indication of OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI] to include the ...
Read More

MHLW Approves New Indication for OLANZAPINE Formulation and New Administration for MEROPENEM Formulation

Osaka, Japan –April 4, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of two partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OLANZAPINE Tablets 2.5mg “SAWAI”, 5mg “SAWAI”, 10mg “SAWAI” and Fine Granules 1% “SAWAI” ...
Read More

Announcement on Sawai Organizational and Personnel Changes

Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018. OrganizationalChanges “Development QA” is renamed “QA Department”. ※The ...
Read More